IRCT20231017059749N1招募中3 期
The augmentation effect of injectable scopolamine in the improvement of clinical symptoms of patients with major depressive disorder
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Patients with major depressive disorder
- •Age 18-55 years
- •Minimum severity of depression based on Hamilton Depression Scale should be higher or equal to 20.
排除标准
- •The existence of psychotic disorder, delirium and bipolar disorderPregnancy or breastfeeding
- •Taking psychedelic drugs, antidepressants in the last month
- •ECT in the last two months
- •History of cardiovascular disease
- •Hypothyroidism
研究者
相似试验
终止
4 期
Muscarinic modulation of human electroencephalography (EEG) activity using scopolamineACTRN12622000228785The University of Auckland12
进行中（未招募）
4 期
To compare Scopolamine versus Ketamine in Treatment Resistant DepressioCTRI/2021/09/036952GMC Patiala
已完成
2 期
Scoploamine in the treatment of major depressioMajor Depressive episode.Major Depressive episodeIRCT201201181556N31Tehran University of Medical Sciences40
尚未招募
2 期
A Clinical trial to study the effect of adding neostigmine to local anaesthetic ropivacaine for painless upper limb surgeriesCTRI/2024/05/067489M S Ramaiah Medical College
招募中
3 期
Sarcomeal oral supplement in treating diabetic sarcopeniaDiabetic sarcopenia.Muscle wasting and atrophy, not elsewhere classifiedM62.5IRCT20230831059311N1Tehran University of Medical Sciences60